NVH MEDICINAL has a total of 12 patent applications. Its first patent ever was published in 2012. It filed its patents most often in EPO (European Patent Office), France and United States. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are SORICIMED BIOPHARMA INC, NO 309 HOSPITAL OF PLA and OXEIA BIOPHARMACEUTICALS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 2 | |
#2 | France | 2 | |
#3 | United States | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Canada | 1 | |
#6 | China | 1 | |
#7 | Republic of Korea | 1 | |
#8 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Vandroux David | 11 |
#2 | De Maistre Emmanuel | 11 |
#3 | Dumont Laure | 7 |
#4 | Dumont Di Leone Laure | 4 |
#5 | Coutard François | 2 |
#6 | Coutard Francois | 2 |
#7 | Vandru David | 1 |
#8 | De Mestr Emmanuel | 1 |
#9 | Dyumon Lora | 1 |
Publication | Filing date | Title |
---|---|---|
US2016310577A1 | Collagen-based injectable preparations capable of controlling bleeding and/or of substituting for platelets in the case of haemorrhagic syndromes | |
EP2908876A1 | Collagen-derived recombinant proteins with von willebrand factor-binding activity |